In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead gets global rights to Tibotec's TMC278

Executive Summary

Gilead Sciences has received exclusive worldwide rights (excluding Japan) to Tibotec Pharmaceuticals' (a Johnson & Johnson division that works on infectious disease therapeutics) TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor. Gilead will combine TMC278 with its Truvada (emtricitabine/tenofovir disoproxil) to create a once-daily fixed-dose antiretroviral therapy for HIV-1 infected adults.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies